FDA Approves Glaxo’s Jesduvroq as Oral Treatment for Anemia

The FDA approved GlaxoSmithKline’s Jesduvroq tablets as the first oral treatment for anemia caused by chronic kidney disease.

• Jesduvroq has a boxed warning for an increased risk of thrombotic vascular events including death, heart attack, according to the FDA

NOTE

• GSK Plc fell 0.3% to GBp1,419.60 as of last close
  • The average 12-month price target of GBp1,626.58 is 14.6% above the current price
  • 13 holds, 11 buys, 3 sells

To view the source of this information, click here

To contact the reporter on this story:
Hari Govind in San Francisco at hgovind@bloomberg.net

To contact the editor responsible for this story: ...